Wang Yuqing, Xu Yiting, Qu Yong, Jin Yifang, Cao Juanmei, Zhan Jinshan, Li Zhuoxia, Chai Chuxing, Huang Changzheng, Li Min
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Central Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Regenerative Medicine and Multi-disciplinary Translational Research, Wuhan 430022, China.
Photodiagnosis Photodyn Ther. 2025 Feb;51:104463. doi: 10.1016/j.pdpdt.2024.104463. Epub 2024 Dec 28.
Although there has been significant progress in current comprehensive anticancer treatments centered on surgery, postoperative recurrence and tumor metastasis still significantly affect both prognosis and quality of life of the patient. Hence, the development of precisely targeted tumor therapies and exploration of immunotherapy represent additional strategies for tumor treatment. Photodynamic therapy (PDT) is a relatively safe treatment modality that not only induces multiple modes of tumor cell death but also mediates the secondary immunological responses against tumor resistance and metastasis. Ferroptosis, an iron-dependent type of programmed cell death characterized by accumulation of reactive oxygen species and lipid peroxidation products to lethal levels, has emerged as an attractive target trigger for tumor therapies. Recent research has revealed a close association between PDT and ferroptosis, suggesting that combining ferroptosis inducers with PDT could strengthen their synergistic anti-tumor efficiency. Here in this review, we discuss the rationale for combining PDT with ferroptosis inducers and highlight the progress of single-molecule photosensitizers to induce ferroptosis, as well as the applications of photosensitizers combined with other therapeutic drugs for collaborative therapy. Furthermore, given the current research dilemma, we propose potential therapeutic strategies to advance the combined usage of PDT and ferroptosis inducers, providing the basis and guidelines for prospective clinical translation and research directionality with regard to PDT.
尽管以手术为中心的当前综合抗癌治疗已取得显著进展,但术后复发和肿瘤转移仍然严重影响患者的预后和生活质量。因此,开发精准靶向肿瘤疗法和探索免疫疗法是肿瘤治疗的额外策略。光动力疗法(PDT)是一种相对安全的治疗方式,不仅能诱导多种肿瘤细胞死亡模式,还能介导针对肿瘤耐药性和转移的继发性免疫反应。铁死亡是一种铁依赖性程序性细胞死亡,其特征是活性氧和脂质过氧化产物积累到致死水平,已成为一种有吸引力的肿瘤治疗靶点触发因素。最近的研究揭示了PDT与铁死亡之间的密切关联,表明将铁死亡诱导剂与PDT联合使用可增强其协同抗肿瘤效率。在本综述中,我们讨论了将PDT与铁死亡诱导剂联合使用的原理,强调了单分子光敏剂诱导铁死亡的进展,以及光敏剂与其他治疗药物联合用于协同治疗的应用。此外,鉴于当前的研究困境,我们提出了潜在的治疗策略,以推进PDT与铁死亡诱导剂的联合使用,为PDT的前瞻性临床转化和研究方向性提供基础和指导。